CPRX - Catalyst Pharmaceuticals Non-GAAP EPS of $0.53 beats by $0.24 revenue of $99.58M beats by $7.87M

2023-08-09 16:23:21 ET

• Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q2 Non-GAAP EPS of $0.53 beats by $0.24 .
• Revenue of $99.58M (+87.5% Y/Y) beats by $7.87M .
• Achieved all-time high total revenues of $99.6 million for Q2 2023, an 87.5% YoY increase, and a 16.7% increase compared to Q1 2023, bolstered by continued organic growth of FIRDAPSE and the addition of FYCOMPA net product revenues.
• Raised 2023 full-year total revenue guidance to between $380 million and $390 million vs $380.23M consensus

For further details see: